Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | Chief Business Officer | July 07, 2017 | July 11, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date July 07, 2017 · Filed July 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.33 · Expires 2027-07-06 | Direct | 32,000 |
Reported balance
After 2017-07-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-07 · Grant · Acquired 32,000 · Balance 32,000 F1: This option vests as to 25% of the shares on June 16, 2018. The remainder of the shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests as to 25% of the shares on June 16, 2018. The remainder of the shares will vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2017 Filed Jul 11, 2017 20:43 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $19.33 | $0.00 |
DisclosureSEC source: 0001638599-17-000698 · doc4_4847.xml · derivative · entry 1 Keller Peter · CIK 0001676904 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2027-07-06 F1 · derivative.exercise_date: This option vests as to 25% of the shares on June 16, 2018. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| June 27, 2017 Filed Jun 28, 2017 20:35 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,595 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001638599-17-000661 · doc4_4823.xml · derivative · entry 3 Keller Peter · CIK 0001676904 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,588 Underlying: Common Stock · 4,595 shares Expires 2021-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares underlying this option are fully vested. Read SEC document |
| June 27, 2017 Filed Jun 28, 2017 20:35 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 4,595 | $19.30 | $88,681.20 |
DisclosureSEC source: 0001638599-17-000661 · doc4_4823.xml · nonDerivative · entry 2 Keller Peter · CIK 0001676904 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.20 to $19.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 27, 2017 Filed Jun 28, 2017 20:35 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | Exercise / conversionCommon Stock | 4,595 | $0.63 | $2,894.85 |
DisclosureSEC source: 0001638599-17-000661 · doc4_4823.xml · nonDerivative · entry 1 Keller Peter · CIK 0001676904 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2016 Filed Dec 22, 2016 00:14 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | SaleCommon Stock | 4,723 | $18.58 | $87,753.34 |
DisclosureSEC source: 0001104659-16-163295 · a4.xml · nonDerivative · entry 1 Keller Peter · CIK 0001676904 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405 F1 · balance_after: These shares are restricted common stock which are subject to a right of repurchase by the Issuer until December 31, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.